FTSE MIB
34.164,70 -131,61 (-0,38%) Dow Jones
38.386,09 +146,43 (+0,38%) Nasdaq
15.983,08 +55,18 (+0,35%) Nikkei 225
38.405,66 +470,90 (+1,24%) Petrolio
82,83 +0,20 (+0,24%) Bitcoin EUR
58.726,11 -631,68 (-1,06%)
INCY Sep 2024 42.500 put
| Chiusura precedente | 0,5200 |
| Aperto | N/D |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 42,50 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 0,5200 - 0,5200 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
